Key clinical point: Majority of patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) who switched from frontline second-generation (2G) tyrosine kinase inhibitor (TKI) to alternative TKIs because of intolerance or resistance were able to achieve or maintain favorable clinical outcomes.
Major finding: Among patients who switched because of intolerance, 88% achieved or maintained a major molecular response (MMR) with 5-year progression-free survival (PFS) and overall survival (OS) of 90.5% (95% confidence interval [CI], 90.4%-90.6%) and 95.2% (95% CI, 95.1%-95.3%), respectively. Among patients who switched because of resistance, 50% achieved or maintained an MMR with 5-year PFS and OS of 80.4% (95% CI, 80.2%-80.6%) and 80.0% (95% CI, 79.8%-80.2%).
Study details : Findings are from a retrospective analysis of 232 patients with newly diagnosed CML-CP treated with frontline 2G-TKI (dasatinib, n=187; nilotinib, n=45) who subsequently switched to alternative TKI.
Disclosures: This study was supported by Pharmacy Services, Alberta Health Services. K Jamani and L Savoie received honoraria from Novartis, Pfizer, Bristol Myers Squibb, and Paladin.
Source: Ma CE et al. Leuk Res. 2021 Jul 24. doi: 10.1016/j.leukres.2021.106674 .